| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022504542 |
| P356 | DOI | 10.1038/243521A0 |
| P953 | full work available at URL | http://www.nature.com/articles/243521a0 |
| http://www.nature.com/articles/243521a0.pdf | ||
| P698 | PubMed publication ID | 4743649 |
| P2093 | author name string | K. G. Lloyd | |
| O. Hornykiewicz | |||
| P2860 | cites work | Role of -aminobutyric acid (GABA) in the extrapyramidal motor system. 2. Some evidence for the existence of a type of GABA-rich strio-nigral neurons | Q42441959 |
| Parkinson's Disease: Activity of L-Dopa Decarboxylase in Discrete Brain Regions | Q43495374 | ||
| Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain | Q48761827 | ||
| Effect of L-DOPA on brain monoamines and their metabolites in Parkinson's disease | Q48824446 | ||
| L‐DOPA: Effect on cerebral pyridoxal phosphate content and coenzyme activity | Q51117796 | ||
| Glutamic acid decarboxylase in Parkinson's disease and epilepsy | Q51119333 | ||
| Effects of globus pallidus lesions and Parkinson's disease on brain glutamic acid decarboxylase. | Q51120966 | ||
| l-DOPA treatment in Parkinson's disease: Effect on dopamine and related substances in discrete brain regions | Q51121102 | ||
| Mechanism of inhibition of histidine decarboxylase (Clostridium welchii) by 4-bromo-3-hydroxybenzyloxamine and amino-oxyacetic acid. | Q54236614 | ||
| P433 | issue | 5409 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P1104 | number of pages | 3 | |
| P304 | page(s) | 521-523 | |
| P577 | publication date | 1973-06-01 | |
| 1973-06-29 | |||
| P1433 | published in | Nature | Q180445 |
| P1476 | title | L-Glutamic Acid Decarboxylase in Parkinson's Disease: Effect of L-Dopa Therapy | |
| P478 | volume | 243 |
| Q64854161 | Q64854161 |
| Q42024321 | Adaptation of the GABAA-receptor complex in rat brain during chronic elevation of GABA by ethanolamine O-sulphate |
| Q36861593 | Adult human olfactory epithelial-derived progenitors: a potential autologous source for cell-based treatment for Parkinson's disease |
| Q48667918 | Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis |
| Q45303735 | Basal ganglia disease |
| Q37019894 | Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases |
| Q68328423 | Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting |
| Q48427284 | Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and Parkinsonian patients |
| Q40085825 | Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications |
| Q36476406 | Epilepsy and γ-Aminobutyric Acid-Mediated Inhibition |
| Q39736473 | GABA content and glutamic acid decarboxylase activity in brain of Huntington's chorea patients and control subjects |
| Q72914837 | GABA in Cerebrospinal Fluid of Children with Febrile Convulsions |
| Q40072465 | GABA in the caudate nucleus: A possible synaptic transmitter of interneurons |
| Q43849359 | Gamma-aminobutyric acidA and benzodiazepine receptor alterations in the rat brain after unilateral 6-hydroxydopamine lesions of the medial forebrain bundle |
| Q43837912 | Glutamic acid decarboxylase in cultured mouse hippocampus and striatum |
| Q39173974 | Historical Aspects and Frontiers of Parkinson’s Disease Research |
| Q49030310 | Imbalance of brain monoamines and clinical disorders |
| Q39463580 | Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses |
| Q44086642 | Interactions of gamma-aminobutyric acid (GABA), pentobarbital, and homopantothenic acid (HOPA) on internally perfused frog sensory neurons |
| Q34075760 | L-Dopa and the Treatment of Extrapyramidal Disease |
| Q34194783 | L-Glutamate Decarboxylase |
| Q45300743 | Letter: G.A.B.A. and Huntington's chorea |
| Q54016164 | Letter: Health care in South Africa. |
| Q45300780 | Letter: Rigidity in Huntington's chorea |
| Q70005847 | Letter: The story of tuberculosis |
| Q64781386 | Low CSF GABA in parkinsonian patients who respond poorly to therapy or suffer from the “on-off” phenomenon |
| Q64761583 | Mapping Spatiotemporal Microproteomics Landscape in Experimental Model of Traumatic Brain Injury Unveils a link to Parkinson's Disease |
| Q40086534 | Neurobiology of Pyridoxine |
| Q34728295 | Neurochemical basis of the therapeutic effect of γ-aminobutyric acid and its derivatives |
| Q40089993 | Neurotransmitter deficits in Alzheimer's disease: criteria for significance |
| Q67278386 | Neutral and Acid Sphingomyelinases of Rat Brain: Somatotopographical Distribution and Activity Following Experimental Manipulation of the Dopaminergic System In Vivo |
| Q28363594 | Parkinson's disease and levodopa. A five-year follow-up and review |
| Q41807762 | Post-mortem changes implicate adenine nucleotides and pyridoxal-5' -phosphate in regulation of brain glutamate decarboxylase |
| Q73372726 | Progressive degeneration of dopamine system functions after transient cerebral oligemia in rats |
| Q39192409 | Regional distribution of enzymes associated with neurotransmission by monoamines, acetylcholine and GABA in the human brain |
| Q71413874 | Relations between dopaminergic and GABAergic mechanisms in avian brain |
| Q28324464 | Sodium valproate in the treatment of levodopa-induced dyskinesia |
| Q39419773 | Success and problems of long-term levodopa therapy in Parkinson's disease |
| Q40083189 | The Potential of GABA-Mimetics in the Therapy of Extrapyramidal Disorders |
| Q41852462 | The biochemical evaluation of psychotropic drugs |
| Q40082826 | The physiology and pharmacology of mammalian basal ganglia |
| Q38075185 | The striatum and substantia nigra: A commentary on their relationships |
| Q49115429 | Therapeutic advances in idiopathic Parkinsonism |
| Q48253391 | Unilateral dopamine depletion paradoxically enhances amphetamine-induced Fos expression in basal ganglia output structures |
| Q49152629 | Visual evoked potentials in hemiparkinsonism |
Search more.